A5068100232- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Hepatitis Viruses Studies and Epidemiology
- Cancer therapeutics and mechanisms
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Liver Disease and Transplantation
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Complementary and Alternative Medicine Studies
- Neuroendocrine Tumor Research Advances
- Glioma Diagnosis and Treatment
- Inflammatory mediators and NSAID effects
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Iron Metabolism and Disorders
- Child Nutrition and Water Access
- Pancreatitis Pathology and Treatment
- Thyroid Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
Hospital South West Jutland
2024
University College South Denmark
2024
Southeastern Medical Oncology Center
2004-2015
Fred Hutch Cancer Center
2007
CancerCare Manitoba
2007
Memorial Sloan Kettering Cancer Center
2007
Cancer Research Center
2007
NSABP Foundation
2006
National Cancer Institute
2006
University of Rochester
2004-2006
LBA4509 Background: Epidermal growth factor receptor [EGFR] pathway is a rational target for therapeutic intervention. This study tested the efficacy of an anti-EGFR monoclonal antibody and gemcitabine [G] combination in Phase III setting patients with advanced PC. Methods: Eligibility included locally unresectable or metastatic PC; adequacy organ function; performance status (PS) 0- 2; no prior EGFR therapy; systemic chemotherapy except adjuvant chemotherapy; submission tumor...
Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks treatment followed by 2 off treatment) in advanced non-small cell lung cancer (NSCLC). We examined the of sunitinib a continuous daily dosing (CDD) schedule an open-label, multicentre phase II study patients with previously treated, NSCLC. Patients ⩾18 years stage IIIB/IV NSCLC after failure platinum-based chemotherapy, received 37.5 mg per day. The primary end point was objective response rate...
BackgroundMasitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent in patients advanced pancreatic ductal adenocarcinoma (PDAC).Patients methodsPatients inoperable, chemotherapy-naïve, PDAC were randomized (1: 1) to receive (1000 mg/m2) combination either (9 mg/kg/day) or placebo. primary endpoint overall survival (OS) the modified intent-to-treat population. Secondary OS analyses aimed...
LBA5 Background: The STAR trial was designed to compare raloxifene tamoxifen in terms of relative effect on invasive breast cancer risk and other beneficial detrimental outcomes associated with the use tamoxifen. Methods: opened 7-1-1999, accrual completed November 4, 2004, 19,747 women enrolled. To be eligible, a woman had postmenopausal 5-year predicted 1.66% as determined by modified Gail model. Women were randomized treated double-blinded fashion receive 5 yr therapy either 20 mg per day...
Minimal hepatic encephalopathy (MHE) is common in liver cirrhosis and identified by psychometric tests. The portosystemic score (PHES) the most widely used serves as an inter-study comparator. PHES has not been standardised for use Danish population, where German normal values have applied until now based on notion that populations are comparable. This study aimed to evaluate if can be population establish needed. 200 217 healthy persons underwent Number Connection Test A B (NCT), Line...
<title>Abstract</title> <bold>Background:</bold> Minimal hepatic encephalopathy (MHE) is common in liver cirrhosis and identified by psychometric tests. The portosystemic score (PHES) the most widely used serves as an inter-study comparator. PHES has not been standardised for use Danish population, where German normal values have applied until now based on notion that populations are comparable. This study aimed to evaluate if can be population establish needed. <bold>Methods: </bold>200 217...
7132 Background: We hypothesized that thalidomide improves the response and toxicity profile of chemotherapy with carboplatin irinotecan because its novel mechanism action (anti-angiogenic, anti-neoplastic, anti-inflammatory) which is different from classic it causes constipation may counteract diarrhea irinotecan. Methods: Treatment consists AUC = 5 iv over 30 min day 1 50 mg/m2 90 8 q 21 days. Thalidomide given continuously po qhs starting on until progressive disease; dose 200 mg/d...
8157 Background: There is an increasing interest in complementary therapies (CT) among health care patients. CT may positively influence perceived and disease processes, however usage not well documented cancer Methods: Cancer patients (N=750) were surveyed on within two weeks of completing standard treatments. Results: Analyses revealed that, 91% (N=677) reported using at least one since diagnosis. Data suggest that women more likely to use than men (p≤.01). Of the surveyed, 68% (N=460)...
8509 Background: Adequate management of cancer related side effects is important for patients yet challenging clinical staff. Cancer treatment have been characterized reasonably well in the literature; however, less known about relationships among response expectancies, personal characteristics, and development chemotherapy-naïve undergoing doxorubicin treatments. Methods: The present sample included 701 from 14 CCOP institutions affiliated with URCC research base. Of total sample, 670...
8157 Background: There is an increasing interest in complementary therapies (CT) among health care patients. CT may positively influence perceived and disease processes, however usage not well documented cancer Methods: Cancer patients (N=750) were surveyed on within two weeks of completing standard treatments. Results: Analyses revealed that, 91% (N=677) reported using at least one since diagnosis. Data suggest that women more likely to use than men (p≤.01). Of the surveyed, 68% (N=460)...
Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies tyrosine kinase inhibitors